Valuation: Axonics, Inc.

Market Cap 362.77Cr 317.14Cr 291.45Cr 271.66Cr 515.27Cr 35TCr 523.08Cr 3.5TCr 1.36TCr 17TCr 1.36TCr 1.33TCr 59TCr P/E 2022
-48.9x
P/E 2023 -502x
Enterprise Value 331.04Cr 289.39Cr 265.95Cr 247.9Cr 470.19Cr 32TCr 477.32Cr 3.19TCr 1.24TCr 15TCr 1.24TCr 1.22TCr 53TCr EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
3 years 48.02
Extreme 48.02
71.05
5 years 38.41
Extreme 38.41
79.92
10 years 11.95
Extreme 11.95
79.92
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/10/2013
Director of Finance/CFO 41 02/10/2023
Chief Operating Officer 47 01/08/2018
Director TitleAgeSince
Director/Board Member 69 01/02/2018
Chairman 55 29/04/2020
Director/Board Member 74 08/04/2019
Date Insider Type Main position Quantity % Market Cap.
15/24/15Issuer sale

Chief Financial Officer

43,487 0.0851%
15/24/15Issuer sale

Responsable ventes & marketing

1,09,664 0.2145%
15/24/15Issuer sale

Chief Operating Officer

1,24,862 0.2443%
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%-.--%-.--%+42.30% 362.77Cr
+4.20%-1.85%-17.39%+9.81% 13TCr
+0.04%-1.01%+1.39%-5.45% 1.28TCr
+7.83%+2.71%+43.32%+112.92% 870.84Cr
+2.29%+7.17%-46.92%-71.82% 406.91Cr
+4.16%+8.39%+25.37%+46.03% 273.22Cr
+2.53%+23.07%-7.66%-13.28% 188.81Cr
+3.55%+8.85%-0.99%-23.70% 166.81Cr
-5.25%-5.89%+179.33%+133.43% 146.42Cr
Average +2.23%+1.10%+19.61%+25.58% 1.8TCr
Weighted average by Cap. +3.83%+2.83%-10.22%+13.94%

Financials

2022 2023
Net sales 27Cr 24Cr 22Cr 20Cr 39Cr 2.61TCr 39Cr 263.98Cr 102.62Cr 1.28TCr 102.74Cr 100.53Cr 4.41TCr 37Cr 32Cr 29Cr 27Cr 52Cr 3.49TCr 53Cr 353.37Cr 137.37Cr 1.71TCr 137.52Cr 134.57Cr 5.91TCr
Net income -5.97Cr -5.22Cr -4.8Cr -4.47Cr -8.48Cr -568.41Cr -8.61Cr -58Cr -22Cr -279.4Cr -22Cr -22Cr -962.8Cr -60.88L -53.22L -48.91L -45.59L -86.47L -58Cr -87.78L -5.87Cr -2.28Cr -28Cr -2.29Cr -2.24Cr -98Cr
Net Debt -35Cr -30Cr -28Cr -26Cr -49Cr -3.31TCr -50Cr -335.73Cr -130.51Cr -1.63TCr -130.66Cr -127.85Cr -5.61TCr -32Cr -28Cr -25Cr -24Cr -45Cr -3.02TCr -46Cr -306.07Cr -118.98Cr -1.49TCr -119.12Cr -116.56Cr -5.12TCr
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
797
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. AXNX Stock